A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder

被引：5
|
作者：
Kao, Chester [1 ]
McNamara, Megan [1 ,2 ,3 ]
Alley, Chris [4 ]
Spector, Neil [1 ,2 ,3 ]
Jauhari, Shekeab [1 ]
Gupta, Rajan T. [5 ]
Zhang, Tian [1 ,2 ]
Zhu, Jason [1 ]
机构：
[1] Duke Univ, Dept Med, Durham, NC USA
[2] Duke Univ, Duke Canc Inst, Durham, NC USA
[3] Durham VA Med Ctr, Dept Hematol & Oncol, Durham, NC USA
[4] Duke Univ, Dept Pathol, Durham, NC 27706 USA
[5] Duke Univ, Dept Radiol, Durham, NC 27710 USA
来源：
CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 03期
关键词：
Bladder cancer; Cisplatin ineligible; Immune checkpoint inhibitors; Metastatic bladder squamous cell carcinoma; PD-1; inhibitor; Psuedoprogression; IMMUNE-RELATED RESPONSE; RADICAL CYSTECTOMY; CISPLATIN; SURVIVAL; THERAPY; PSEUDOPROGRESSION; METHOTREXATE; VINBLASTINE; DOXORUBICIN; OUTCOMES;
D O I：
10.1016/j.clgc.2019.03.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E672 / E677
页数：6
相关论文
共 50 条
  • [31] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, Hsiang-Fong
    Huang, Huai-Cheng
    Liao, Bin-Chi
    Hong, Ruey-Long
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [32] Metastatic Squamous Cell Carcinoma Treated With Pembrolizumab in a Patient With Xeroderma Pigmentosum
    Do, Ngan
    Smith, Robert J.
    Choi, Sara
    Queenan, Maria
    Larijani, Mary
    PEDIATRIC DERMATOLOGY, 2025,
  • [33] Complete Remission by Pembrolizumab Therapy after initial Progression in a Patient with metastatic Uveamelanoma
    Stauner, Toledo C.
    Drexler, K.
    Berneburg, M.
    Haferkamp, S.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 18 - 18
  • [34] Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series
    Plais, Henri
    Dumont, Clement
    Gauthier, Helene
    Culine, Stephane
    IMMUNOTHERAPY, 2023, 15 (10) : 729 - 735
  • [35] Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report
    Zeng, Tian
    Zhang, Lei
    Chen, Can
    Zhao, Xiang
    Liu, Xiaoqing
    Ran, Fengwei
    Yong, Tingting
    Yang, Ying
    Zhang, Henghui
    Zhang, Yanling
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [36] Complete response of squamous cell carcinoma of the lung following treatment with pembrolizumab in an elderly patient: A case report
    Takeuchi, Eiji
    Okamoto, Yuri
    Takahashi, Naoki
    Morizumi, Shun
    Toyoda, Yuko
    Kuroda, Naoto
    Yorita, Kenji
    THORACIC CANCER, 2021, 12 (02) : 259 - 263
  • [37] Metastatic squamous cell carcinoma of the cervix: complete response under maintenance strategy with bevacizumab
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 828 - 829
  • [38] Metastatic small-cell carcinoma of the bladder that maintains a complete response to chemoradiation therapy
    Miyazaki, Shinya
    Ueda, Takashi
    Tamai, Ryosuke
    Ueno, Akihisa
    Nakamura, Terukazu
    IJU CASE REPORTS, 2023, 6 (01) : 81 - 84
  • [39] Massive Periocular Squamous Cell Carcinoma With Response to Pembrolizumab (Keytruda)
    Conger, Jordan R.
    Grob, Seanna R.
    Tao, Jeremiah
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2019, 35 (05): : E127 - E127
  • [40] Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
    Robert, Caroline
    Ribas, Antoni
    Hamid, Omid
    Daud, Adil
    Wolchok, Jedd D.
    Joshua, Anthony M.
    Hwu, Wen-Jen
    Weber, Jeffrey S.
    Gangadhar, Tara C.
    Joseph, Richard W.
    Dronca, Roxana
    Patnaik, Amita
    Zarour, Hassane
    Kefford, Richard
    Hersey, Peter
    Zhang, Jin
    Anderson, James
    Diede, Scott J.
    Ebbinghaus, Scot
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1668 - +
12345